USA, PrimeraDx Closes $20M Series C Financing Round

PrimeraDx, Inc., a molecular diagnostics company, closed its $20 million Series C financing round.
The round was led by CHL Medical Partners with the participation from existing investors Abingworth, InterWest Partners, Malaysian Technology Development Corporation, MPM Capital, Burrill &Company and the Invus Group.
Explaining how the Mansfield, MA.-based PrimeraDx will use the proceeds, from the financing, Martin L. Verhoef, President and Chief Executive Officer, said: “We will use this funding for the continued commercialization of our technology, including the advancement of our regulatory strategy and the broadening of quantitative, multiplexed assay menu to run on our ICEPlex system”.

Join the discussion